L
Loretta M. Itri
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 8
Citations - 1564
Loretta M. Itri is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Chemotherapy & Vindesine. The author has an hindex of 5, co-authored 8 publications receiving 1552 citations.
Papers
More filters
Journal ArticleDOI
Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid).
Raymond P. Warrell,Stanley R. Frankel,Wilson H. Miller,David A. Scheinberg,Loretta M. Itri,Walter N. Hittelman,Rohini Vyas,Michael Andreeff,Agostino Tafuri,Ann A. Jakubowski,Janice Gabrilove,Michael Gordon,Ethan Dmitrovsky +12 more
TL;DR: Tretinoin is a safe and highly effective agent for inducing complete remission in patients with acute promyelocytic leukemia and clinical response to this agent is associated with leukemic-cell differentiation and is linked to the expression of an aberrant RAR-alpha nuclear receptor.
Journal ArticleDOI
Resistance to Recombinant Interferon Alfa-2a in Hairy-Cell Leukemia Associated with Neutralizing Anti-Interferon Antibodies
Ronald G. Steis,John W. Smith,Walter J. Urba,Jeffrey W. Clark,Loretta M. Itri,Lydia Evans,Carolyn S. Schoenberger,Dan L. Longo +7 more
TL;DR: The data suggest that the development of clinical resistance to interferon alfa-2a in hairy-cell leukemia is not necessarily related to an altered cellular response tointerferon, and treatment with other interferons, such as purified natural interfer on alfa, may be useful in patients with clinically important neutralizing antibodies against interfero-2A.
Journal ArticleDOI
Cisplatin, vindesine and bleomycin (CVB) combination chemotherapy of advanced non‐small cell lung cancer
Loretta M. Itri,Richard J. Gralla,David P. Kelsen,R. Chapman,Ephraim S. Casper,David W. Braun,Jane Howard,Robert B. Golbey,Robert T. Heelan +8 more
TL;DR: The response rate and survival duration produced by the CVB protocol were similar to those reported for the two‐drug combination of vindesine and high‐dose cisplatin, and the addition of a four‐day bleomycin infusion did not appear to offer a significant advantage.
Journal ArticleDOI
Phase II trial of VP16-213 in non-small cell lung cancer (NSCLC).
R. Chapman,Loretta M. Itri,Richard J. Gralla,David P. Kelsen,Ephraim S. Casper,Robert B. Golbey +5 more
TL;DR: It is concluded that VP16-213 has only minimal activity as a single agent in NSCLC and myelosuppression was the dose limiting toxicity.
Journal ArticleDOI
Phase II trial of VP-16-213 in non-small-cell lung cancer.
Loretta M. Itri,Richard J. Gralla,R. Chapman,David P. Kelsen,Ephraim S. Casper,Robert B. Golbey +5 more
TL;DR: It is concluded that VP-16-213 has minimal activity as a single agent in NSCLC.